Literature DB >> 24036388

Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles.

Alejandra Nieto1, Huiyuan Hou, Michael J Sailor, William R Freeman, Lingyun Cheng.   

Abstract

Porous silicon (pSi) microparticles have been investigated for intravitreal drug delivery and demonstrated good biocompatibility. With the appropriate surface chemistry, pSi can reside in vitreous for months or longer. However, ocular distribution and clearance pathway of its degradation product, silicic acid, are not well understood. In the current study, rabbit ocular tissue was collected at different time point following fresh pSi (day 1, 5, 9, 16, and 21) or oxidized pSi (day 3, 7, 14, 21, and 35) intravitreal injection. In addition, dual-probe simultaneous microdialysis of aqueous and vitreous humor was performed following a bolus intravitreal injection of 0.25 mL silicic acid (150 μg/mL) and six consecutive microdialysates were collected every 20 min. Silicon was quantified from the samples using inductively coupled plasma-optical emission spectroscopy. The study showed that following the intravitreal injection of oxidized pSi, free silicon was consistently higher in the aqueous than in the retina (8.1 ± 6.5 vs. 3.4 ± 3.9 μg/mL, p = 0.0031). The area under the concentration-time curve (AUC) of the retina was only about 24% that of the aqueous. The mean residence time was 16 days for aqueous, 13 days for vitreous, 6 days for retina, and 18 days for plasma. Similarly, following intravitreal fresh pSi, free silicon was also found higher in aqueous than in retina (7 ± 4.7 vs. 3.4 ± 4.1 μg/mL, p = 0.014). The AUC for the retina was about 50% of the AUC for the aqueous. The microdialysis revealed the terminal half-life of free silicon in the aqueous was 30 min and 92 min in the vitreous; the AUC for aqueous accounted for 38% of the AUC for vitreous. Our studies indicate that aqueous humor is a significant pathway for silicon egress from the eye following intravitreal injection of pSi crystals.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  intravitreal porous silicon; ocular drug delivery; ocular silicon clearance; rabbit eye

Mesh:

Substances:

Year:  2013        PMID: 24036388      PMCID: PMC3873878          DOI: 10.1016/j.exer.2013.09.001

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  23 in total

1.  Determination of silicon in biological samples by ICP-OES after non-oxidative decomposition under alkaline conditions.

Authors:  S Hauptkorn; J Pavel; H Seltner
Journal:  Fresenius J Anal Chem       Date:  2001-06

2.  The turnove of bromide in the rabbit eye.

Authors:  B BECKER
Journal:  Arch Ophthalmol       Date:  1961-06

3.  A comparative study of the total carbon dioxide in the ocular fluids, cerebrospinal fluid, and plasma of some mammalian species.

Authors:  H DAVSON; C P LUCK
Journal:  J Physiol       Date:  1956-05-28       Impact factor: 5.182

4.  The loss of fluorescein, fluorescein glucuronide and fluorescein isothiocyanate dextran from the vitreous by the anterior and retinal pathways.

Authors:  M Araie; D M Maurice
Journal:  Exp Eye Res       Date:  1991-01       Impact factor: 3.467

Review 5.  Mesoporous silicon in drug delivery applications.

Authors:  Jarno Salonen; Ann M Kaukonen; Jouni Hirvonen; Vesa-Pekka Lehto
Journal:  J Pharm Sci       Date:  2008-02       Impact factor: 3.534

6.  Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle.

Authors:  L Cheng; E Anglin; F Cunin; D Kim; M J Sailor; I Falkenstein; A Tammewar; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-05       Impact factor: 4.638

7.  Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir.

Authors:  Lingyun Cheng; Karl Y Hostetler; Jeffery Lee; Hyoung Jun Koh; James R Beadle; Kenichiro Bessho; Mitsuko Toyoguchi; Kathy Aldern; Jean-Marc Bovet; William R Freeman
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-11       Impact factor: 4.799

8.  Evaluation of mammalian cell adhesion on surface-modified porous silicon.

Authors:  Suet Peng Low; Keryn A Williams; Leigh T Canham; Nicolas H Voelcker
Journal:  Biomaterials       Date:  2006-05-16       Impact factor: 12.479

9.  Copper and zinc distribution in the human retina: relationship to cadmium accumulation, age, and gender.

Authors:  N K Wills; V M Sadagopa Ramanujam; N Kalariya; J R Lewis; F J G M van Kuijk
Journal:  Exp Eye Res       Date:  2008-05-07       Impact factor: 3.467

Review 10.  Porous silicon in drug delivery devices and materials.

Authors:  Emily J Anglin; Lingyun Cheng; William R Freeman; Michael J Sailor
Journal:  Adv Drug Deliv Rev       Date:  2008-04-10       Impact factor: 15.470

View more
  13 in total

1.  Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.

Authors:  Kaihui Nan; Feiyan Ma; Huiyuan Hou; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Acta Biomater       Date:  2014-05-02       Impact factor: 8.947

2.  Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.

Authors:  Chengyun Wang; Huiyuan Hou; Kaihui Nan; Michael J Sailor; William R Freeman; Lingyun Cheng
Journal:  Exp Eye Res       Date:  2014-11-05       Impact factor: 3.467

3.  Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin.

Authors:  Alejandra Nieto; Huiyuan Hou; Sang Woong Moon; Michael J Sailor; William R Freeman; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-01-22       Impact factor: 4.799

4.  Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.

Authors:  Huiyuan Hou; Alejandra Nieto; Feiyan Ma; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  J Control Release       Date:  2014-01-11       Impact factor: 9.776

5.  The Effect of Silica Nanoparticles on Human Corneal Epithelial Cells.

Authors:  Joo-Hee Park; Hyejoong Jeong; Jinkee Hong; Minwook Chang; Martha Kim; Roy S Chuck; Jimmy K Lee; Choul-Yong Park
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

6.  A sustained intravitreal drug delivery system with remote real time monitoring capability.

Authors:  Huiyuan Hou; Alejandra Nieto; Akram Belghith; Kaihui Nan; Yangyang Li; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Acta Biomater       Date:  2015-06-15       Impact factor: 8.947

7.  Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide.

Authors:  Huiyuan Hou; Chengyun Wang; Kaihui Nan; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-02       Impact factor: 4.799

8.  Safety of Nonporous Silica Nanoparticles in Human Corneal Endothelial Cells.

Authors:  Ja-Yeon Kim; Joo-Hee Park; Martha Kim; Hyejoong Jeong; Jinkee Hong; Roy S Chuck; Choul Yong Park
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

9.  Intravitreal safety profiles of sol-gel mesoporous silica microparticles and the degradation product (Si(OH)4).

Authors:  Yaoyao Sun; Kristyn Huffman; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

10.  Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy.

Authors:  David Warther; Ying Xiao; Fangting Li; Yuqin Wang; Kristyn Huffman; William R Freeman; Michael Sailor; Lingyun Cheng
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.